N7-methylguanosine (m7G) modification in breast cancer: clinical significances and molecular mechanisms.

IF 6 2区医学 Q1 ONCOLOGY

Cancer Cell International Pub Date : 2025-08-12 DOI:10.1186/s12935-025-03859-y

Tianyao Yang, Chunyan Chen, Fangfang Wang, Lan Yue

{"title":"N7-methylguanosine (m7G) modification in breast cancer: clinical significances and molecular mechanisms.","authors":"Tianyao Yang, Chunyan Chen, Fangfang Wang, Lan Yue","doi":"10.1186/s12935-025-03859-y","DOIUrl":null,"url":null,"abstract":"<p><p>The therapeutic strategies for advanced breast cancer (BC) continue to present significant challenges. Consequently, the implementation of precise diagnostic biomarkers and prognostic targets is essential for effective BC management. Recently, N7-methylguanosine (m7G) modification has garnered considerable attention in the context of various cancer types. In this study, we conducted a comprehensive literature review to explore the potential role of m7G in the tumorigenesis of BC. Analysis of thirteen relevant studies revealed that m7G methyltransferases were usually aberrantly expressed in BC, including TNBC and breast invasive carcinoma. m7G modifications in mRNA, tRNA, and rRNA can ultimately affect the expression of target genes (i.e., m7G regulators [e.g., METTL1/WDR4], m7G-associated genes [e.g. P27 and AGO2], m7G-related lncRNAs [e.g., LINC01871 and LINC00115], and m7G-related miRNAs [e.g. miR-7 and miR-139]) and regulate BC-related biological functions. These novel insights indicate that m7G modification and its regulators hold significant potential for future clinical applications in the diagnosis and treatment of BC. In the future, how to apply m7G modifications to identify the implementation of clinically personalized BC treatment needs to be further explored.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"303"},"PeriodicalIF":6.0000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12341331/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-025-03859-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The therapeutic strategies for advanced breast cancer (BC) continue to present significant challenges. Consequently, the implementation of precise diagnostic biomarkers and prognostic targets is essential for effective BC management. Recently, N7-methylguanosine (m7G) modification has garnered considerable attention in the context of various cancer types. In this study, we conducted a comprehensive literature review to explore the potential role of m7G in the tumorigenesis of BC. Analysis of thirteen relevant studies revealed that m7G methyltransferases were usually aberrantly expressed in BC, including TNBC and breast invasive carcinoma. m7G modifications in mRNA, tRNA, and rRNA can ultimately affect the expression of target genes (i.e., m7G regulators [e.g., METTL1/WDR4], m7G-associated genes [e.g. P27 and AGO2], m7G-related lncRNAs [e.g., LINC01871 and LINC00115], and m7G-related miRNAs [e.g. miR-7 and miR-139]) and regulate BC-related biological functions. These novel insights indicate that m7G modification and its regulators hold significant potential for future clinical applications in the diagnosis and treatment of BC. In the future, how to apply m7G modifications to identify the implementation of clinically personalized BC treatment needs to be further explored.

查看原文本刊更多论文

n7 -甲基鸟苷（m7G）修饰在乳腺癌中的临床意义及分子机制

晚期乳腺癌（BC）的治疗策略继续面临重大挑战。因此，实施精确的诊断生物标志物和预后目标对于有效的BC管理至关重要。近年来，n7 -甲基鸟苷（m7G）修饰在各种癌症类型中引起了相当大的关注。在这项研究中，我们进行了全面的文献综述，探讨m7G在BC肿瘤发生中的潜在作用。对13项相关研究的分析显示，m7G甲基转移酶通常在BC中异常表达，包括TNBC和乳腺浸润性癌。m7G在mRNA、tRNA和rRNA中的修饰最终可影响靶基因（即m7G调控因子[如METTL1/WDR4]、m7G相关基因[如P27和AGO2]、m7G相关lncrna[如LINC01871和LINC00115]、m7G相关mirna[如miR-7和miR-139]）的表达，并调节bc相关的生物学功能。这些新发现表明，m7G修饰及其调节因子在BC的诊断和治疗中具有重要的临床应用潜力。在未来，如何应用m7G修饰来识别临床个性化BC治疗的实施还需要进一步探索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.